
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's outlook is bolstered by anticipated procedural growth, with projections indicating a modest 5-10% increase in combined atrial fibrillation (AF) ablation and left atrial appendage closure (LAAC) procedures, alongside a potential 20-30% volume increase driven by positive CHAMPION-AF trial outcomes. The company is expected to capture significant market growth, with the global AFib market anticipated to rise from $9 billion to $15 billion by 2028, alongside its electrophysiology (EP) market growing to approximately $20 billion, reflecting a compound annual growth rate (CAGR) of 15%. Positive survey trends suggest healthcare professionals foresee an average 18% increase in procedure volumes stemming from recent trial results, underscoring strong demand for Boston Scientific's innovative medical devices.
Bears say
Boston Scientific faces a negative outlook due to a projected decline in its core ablation product segments, with radiofrequency ablation sales expected to decrease by 1,110 basis points and cryoablation by 500 basis points by 2030. Additional headwinds include slower-than-expected adoption of its product portfolio, limited operational leverage with operating margin expansion falling short of its goals, and the potential for increased debt levels from mergers and acquisitions adversely affecting its financial leverage. Furthermore, competition in key markets, delays in product approvals, and risks associated with clinical trials could further hamper the company’s future growth prospects.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares